Novo Is On Track To File Liraglutide For Obesity By 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk reported positive data from a Phase III trial of liraglutide in sleep apnea, completing the drug’s clinical program in obesity. It expects to file for regulatory approval of the drug as a weight reducer by year end.
You may also be interested in...
Novo Nordisk Lays Out Obesity Commercial Strategy, Ahead of Liraglutide FDA Submission
Reimbursement and sales strategy for liraglutide 3 mg to treat obesity, which the pharma hopes to launch in 2015, are a focus as the pharma laid out its long-term plans in an analyst meeting on Dec. 3. It suggested payers, who aren’t embracing new obesity drugs, could try patients on the drug for a trial period and proceed only with the best responders.
Novo Plans Phase III Program To Pick Up Obesity Claim For Victoza
Novo Nordisk is moving ahead with plans to develop Victoza (liraglutide) for obesity now that U.S. regulators are comfortable with the GLP-1's risk/benefit profile.
Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?